The pharmacoinvasive strategy is a modern approach to ST-elevation myocardial infarction (STEMI). According to it, the healthcare provider uses a fibrinolytic drug immediately after the diagnose of STEMI, with a routine transference of the patient (if clinically stable) to a tertiary hospital, between 3 and 24 hours after the administration of the medication, in order for him/her to be submitted to a coronary angiography and percutaneous coronary intervention (PCI) if feasible. This strategy has already proved itself safe and efficacious in different studies, being used in healthcare units/hospitals without angioplasty capability, or even at centers with PCI capability but unable to immediately submit a specific patient to the procedure (generally due to technical problems). On the other hand, the predictive value of ischemic risk scores for patients with STEMI has been widely studied in patients treated with fibrinolytic or primary PCI isolated, being incorporated in different guidelines for these situations. However, the value of the same risk scores, to be best of our knowledge, has never been analyzed previously in patients submitted to a pharmacoinvasive strategy; the answer to this question is the main purpose of the present project - in order to fulfill that, two of the most worldwide utilized risk scores (TIMI and GRACE) will be tested in a Brazilian population included prospectively and consecutively in dedicated databank.
News published in Agência FAPESP Newsletter about the scholarship: